Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin plus thalidomide versus doxorubicin alone in unresectable hepatocellular carcinoma
ISRCTN53872240Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Jun 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin and thalidomide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Erasmus MC. Primary endpoint: One-year survival. Started Jun 2004; status: completed.
02
Drugs
doxorubicinthalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN53872240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53872240.